Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00545610 · ClinicalTrials.gov registry record

ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)

A clinical trial, sponsored by Lisata Therapeutics.

Completed
Registry status
150
Enrollment target

NCT00545610 is a clinical trial that has completed, run by Lisata Therapeutics. The registered enrollment target is 150 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00545610 has completed, sponsored by Lisata Therapeutics.

COMPLETED
Registry status
150 participants
Enrollment target

Study Summary

The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+ cells on quality of life (QoL) in subjects with chronic refractory myocardial ischemia. No treatments will be administered during this study. However, the investigators and other study site personnel and the subjects will remain blinded to the treatment assignments from the core therapeutic study (# 24779) so as to provide a total of 24 months of blinded data.

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2007-10
Est. Completion 2010-06

Sponsor

Lisata Therapeutics

12 total trials

What the Registry Record Tells You About NCT00545610

The ClinicalTrials.gov registry entry for NCT00545610 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lisata Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00545610 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00545610 about?

NCT00545610 is a clinical study titled "ACT34-CMI -- Adult Autologous CD34+ Stem Cells (Follow-Up Study)". The purpose of this 12-month, observational, follow-up study is to collect additional data (by telephone contact) with which to assess the efficacy, safety, and effects of intramyocardial injections of adult autologous CD34+ cells on quality of life (QoL) in subjects with chronic refractory myocardi...

What is the current status of trial NCT00545610?

This trial is currently completed. The enrollment target is 150 participants. The study started on 2007-10. Estimated completion is 2010-06.

Who is sponsoring clinical trial NCT00545610?

This trial is sponsored by Lisata Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.